Clinical trial
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects
NCT02268864 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects
- Lead sponsor
- Janssen-Cilag International NV
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- April 30, 2016
- Enrollment
- 106 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.